GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Heidelberg Pharma HPHA.DE · EUR

Health Care · XETRA · 🇩🇪 Germany

Compare

2.19

+2.34%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Heidelberg Pharma

Its shares trade on XETRA under the ticker HPHA.DE. It has been listed since 13 November 2006. In the fiscal year to 30 November 2025, it reported revenue of €1.5m and a net loss of €42.3m. At that date it held total assets of €38.1m and shareholders' equity of −€10.9m.

Heidelberg Pharma AG is a holding company, which engages in the development of diagnostic and therapeutic oncology products for the detection and targeted treatment of various types of cancer. The company is headquartered in Ladenburg, Baden-Wuerttemberg. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Nov 2006
Employees
72

Leadership

Pay as last reported

  • Prof. Dr. Christof HettichChairman of the Supervisory Board, since 2010€49,500
  • Prof. Dr. Andreas PahlChief Executive Officer, Member of the Executive Management Board€477,071
  • Dr. Georg BaurDeputy Chairman of the Supervisory Board€38,000
  • Dr. Mathias HothumDeputy Chairman of the Supervisory Board, since 2015€34,000
  • Mr. Walter MillerChief Financial Officer, Member of the Executive Management Board€316,000
  • Dr. Birgit KudlekMember of the Supervisory Board€21,000
  • Dr. Dongzhou LiuMember of the Supervisory Board€21,000
  • Dr. Friedrich Von Bohlen Und HalbachMember of the Supervisory Board€18,750
  • Dr. Yan XiaMember of the Supervisory Board€18,000
  • Ms. Katja ArnoldIR Contact Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Heidelberg Pharma AG possesses several strengths that contribute to its competitive advantage in the market:

Weaknesses

  • Despite its strengths, Heidelberg Pharma AG faces certain weaknesses that may hinder its performance and growth:

Opportunities

  • Heidelberg Pharma AG can capitalize on the following opportunities to drive future growth and success:

Threats

  • Heidelberg Pharma AG should be wary of the following threats that may pose challenges to its business:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.